Skip to main content Accesibility Help
×
×
Home

Conducting clinical studies targeting cognition in psychiatry: guiding principles and design

  • Tamsyn E. Van Rheenen (a1) (a2) (a3), Kathryn E. Lewandowski (a4) (a5), Jessica M. Lipschitz (a5) (a6) and Katherine E. Burdick (a5) (a6)
Abstract

Cognitive dysfunction is common in many psychiatric disorders. While it has long been described as a core feature in schizophrenia, more recent data suggest qualitatively similar impairments in patients with bipolar disorder and major depressive disorder. There is compelling evidence to suggest that cognitive impairment contributes directly to functional disability and reduced quality of like across these disorders. As current treatments focus heavily on “primary” symptoms of mood and psychosis, the standard of care typically leaves cognitive deficits unmanaged. With this in mind, the field has recently begun to consider intervening directly on this important symptom domain, with several ongoing trials in schizophrenia. Fewer studies have targeted cognition in bipolar disorder and still fewer in MDD. With progress toward considering this domain as a target for treatment comes the need for consensus guidelines and methodological recommendations on cognitive trial design. In this manuscript, we first summarize the work conducted to date in this area for schizophrenia and for bipolar disorder. We then begin to address these same issues in MDD and emphasize the need for additional work in this area.

Copyright
Corresponding author
*Address for correspondence: Katherine E. Burdick, PhD, Brigham and Women’s Hospital, 221 Longwood Ave., Boston, MA 02119, USA. (Email: kburdick1@bwh.harvard.edu)
References
Hide All
1. Buchanan, RW, Keefe, RSE, Umbricht, D, Green, MF, Laughren, T, Marder, SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull. 2011;37(6):12091217. doi:10.1093/schbul/sbq038
2. Buchanan, RW, Davis, M, Goff, D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):519. doi:10.1093/schbul/sbi020
3. Nuechterlein, KH, Green, MF, Kern, RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165(2):203213. doi:10.1176/appi.ajp.2007.07010042
4. Dean, OM, Gliddon, E, Van Rheenen, TE, et al. An update on adjunctive treatment options for bipolar disorder. Bipolar Disord. 2018;20(2):8796. doi:10.1111/bdi.12601
5. Burdick, KE, Braga, RJ, Goldberg, JF, Malhotra, AK. Cognitive dysfunction in bipolar disorder: future place of pharmacotherapy. CNS Drugs. 2007;21(12):971981.
6. Burdick, KE, Goldberg, JF, Harrow, M, Faull, RN, Malhotra, AK. Neurocognition as a stable endophenotype in bipolar disorder and schizophrenia. J Nerv Ment Dis. 2006;194(4):255260. doi:10.1097/01.nmd.0000207360.70337.7e
7. Burdick, KE, Ketter, TA, Goldberg, JF, Calabrese, JR. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry. 2015;76(3):e342e350. doi:10.4088/JCP.14cs09399
8. Kern, RS, Nuechterlein, KH, Green, MF, et al. The MATRICS consensus cognitive battery, part 2: co-norming and standardization. Am J Psychiatry. 2008;165(2):214220. doi:10.1176/appi.ajp.2007.07010043
9. Van Rheenen, TE, Lewandowski, KE, Tan, EJ, et al. Characterizing cognitive heterogeneity on the schizophrenia–bipolar disorder spectrum. Psychol Med. 2017;47(10):18481864. doi:10.1017/S0033291717000307
10. Van Rheenen, TE, Bryce, S, Tan, EJ, et al. Does cognitive performance map to categorical diagnoses of schizophrenia, schizoaffective disorder and bipolar disorder? A discriminant functions analysis. J Affect Disord. 2016;192:109115. doi:10.1016/j.jad.2015.12.022
11. Harvey, PD, Siever, LJ, Huang, GD, et al. The genetics of functional disability in schizophrenia and bipolar illness: methods and initial results for VA cooperative study #572. Am J Med Genet B Neuropsychiatr Genet. 2014;165B(4):381389. doi:10.1002/ajmg.b.32242
12. Barch, DM, Sheffield, JM. Cognitive impairments in psychotic disorders: common mechanisms and measurement. World Psychiatry. 2014;13(3):224232. doi:10.1002/wps.20145
13. Yatham, LN, Torres, IJ, Malhi, GS, et al. The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC). Bipolar Disord. 2010;12(4):351363. doi:10.1111/j.1399-5618.2010.00830.x
14. Miskowiak, KW, Burdick, KE, Martinez-Aran, A, et al. Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force. Bipolar Disord. 2017;19(8):614626. doi:10.1111/bdi.12534
15. Burdick, KE, Goldberg, TE, Cornblatt, BA, et al. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology. 2011;36(8):15871592. doi:10.1038/npp.2011.36
16. Van Rheenen, TE, Rossell, SL. An empirical evaluation of the MATRICS Consensus Cognitive Battery in bipolar disorder. Bipolar Disord. 2014;16(3):318325. doi:10.1111/bdi.12134
17. Van Rheenen, TE. Commentary on “Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.” Bipolar Disord. 2018;20(1):7273. doi:10.1111/bdi.12577
18. Lewandowski, KE. Hastening treatment development in bipolar disorder: evaluation of consensus-based recommendations for cognition trials. Bipolar Disord. 2018;20(1):7071. doi:10.1111/bdi.12578
19. Millan, MJ, Agid, Y, Brüne, M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141168. doi:10.1038/nrd3628
20. Nierenberg, AA, Husain, MM, Trivedi, MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):4150. doi:10.1017/S0033291709006011
21. Davis, MT, DellaGioia, N, Matuskey, D, et al. Preliminary evidence concerning the pattern and magnitude of cognitive dysfunction in major depressive disorder using cogstate measures. J Affect Disord. 2017;218:8285. doi:10.1016/j.jad.2017.04.064
22. McIntyre, RS, Best, MW, Bowie, CR, et al. The THINC-Integrated Tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78(7):873881. doi:10.4088/JCP.16m11329
23. Knight, MJ, Baune, BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31(1):2631. doi:10.1097/YCO.0000000000000378
24. McIntyre, RS, Lee, Y. Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI). Curr Opin Psychiatry. 2016;29(1):4855. doi:10.1097/YCO.0000000000000221
25. Russo, M, Mahon, K, Burdick, KE. Measuring cognitive function in MDD: emerging assessment tools. Depress Anxiety. 2015;32(4):262269. doi:10.1002/da.22297
26. Wagner, S, Doering, B, Helmreich, I, Lieb, K, Tadić, A. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand. 2012;125(4):281292. doi:10.1111/j.1600-0447.2011.01762.x
27. Lee, RSC, Hermens, DF, Porter, MA, Redoblado-Hodge, MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140(2):113124. doi:10.1016/j.jad.2011.10.023
28. Lee, RSC, Hermens, DF, Naismith, SL, et al. Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: a longitudinal cohort study. Transl Psychiatry. 2015;5:e555. doi:10.1038/tp.2015.50
29. Hasselbalch, BJ, Knorr, U, Hasselbalch, SG, Gade, A, Kessing, LV. The cumulative load of depressive illness is associated with cognitive function in the remitted state of unipolar depressive disorder. Eur Psychiatry. 2013;28(6):349355. doi:10.1016/j.eurpsy.2012.03.004
30. Hasselbalch, BJ, Knorr, U, Hasselbalch, SG, Gade, A, Kessing, LV. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology. 2012;26(5):642651. doi:10.1037/a0029301
31. Paelecke-Habermann, Y, Pohl, J, Leplow, B. Attention and executive functions in remitted major depression patients. J Affect Disord. 2005;89(1–3):125135. doi:10.1016/j.jad.2005.09.006
32. Miskowiak, K, Vinberg, M, Christensen, EM, Kessing, LV. Is there a difference in subjective experience of cognitive function in patients with unipolar disorder versus bipolar disorder? Nord J Psychiatry. 2012;66(6):389395. doi:10.3109/08039488.2012.658862
33. Green, MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67(10):e12.
34. Burdick, KE, Goldberg, JF, Harrow, M. Neurocognitive dysfunction and psychosocial outcome in patients with bipolar I disorder at 15-year follow-up. Acta Psychiatr Scand. 2010;122(6):499506. doi:10.1111/j.1600-0447.2010.01590.x
35. Motter, JN, Pimontel, MA, Rindskopf, D, Devanand, DP, Doraiswamy, PM, Sneed, JR. Computerized cognitive training and functional recovery in major depressive disorder: a meta-analysis. J Affect Disord. 2016;189:184191. doi:10.1016/j.jad.2015.09.022
36. Baune, BT, Air, T. Clinical, functional, and biological correlates of cognitive dimensions in major depressive disorder - rationale, design, and characteristics of the Cognitive Function and Mood Study (CoFaM-Study). Front Psychiatry. 2016;7:150. doi:10.3389/fpsyt.2016.00150
37. Baune, BT, Miller, R, McAfoose, J, Johnson, M, Quirk, F, Mitchell, D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2–3):183189. doi:10.1016/j.psychres.2008.12.001
38. Clark, M, DiBenedetti, D, Perez, V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):455463. doi:10.1080/14737167.2016.1195688
39. Cha, DS, Carmona, NE, Subramaniapillai, M, et al. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): association with psychosocial function in major depressive disorder. J Affect Disord. 2017;222:1420. doi:10.1016/j.jad.2017.06.036
40. Barlati, S, Deste, G, De Peri, L, Ariu, C, Vita, A. Cognitive remediation in schizophrenia: current status and future perspectives. Schizophr Res Treat. 2013;2013:156084. doi:10.1155/2013/156084
41. Anguera, JA, Gunning, FM, Areán, PA. Improving late life depression and cognitive control through the use of therapeutic video game technology: a proof-of-concept randomized trial. Depress Anxiety. 2017;34(6):508517. doi:10.1002/da.22588
42. Arean, PA, Hallgren, KA, Jordan, JT, et al. The use and effectiveness of mobile apps for depression: results from a fully remote clinical trial. J Med Internet Res. 2016;18(12):e330. doi:10.2196/jmir.6482
43. Oh, SJ, Seo, S, Lee, JH, Song, MJ, Shin, M-S. Effects of smartphone-based memory training for older adults with subjective memory complaints: a randomized controlled trial. Aging Ment Health. 2018;22(4):526534. doi:10.1080/13607863.2016.1274373
44. Howells, A, Ivtzan, I, Eiroa-Orosa, FJ. Putting the ‘app’ in happiness: a randomised controlled trial of a smartphone-based mindfulness intervention to enhance wellbeing. Journal of Happiness Studies. 2016;17(1):163185. doi:10.1007/s10902-014-9589-1
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed